Published in Nat Med on July 31, 2011
A Crossover Pilot Study of the Effect of Amiloride on Proteinuria | NCT02522650
Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med (2015) 4.85
Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice. J Am Soc Nephrol (2014) 2.91
Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol (2012) 2.83
Cell biology and pathology of podocytes. Annu Rev Physiol (2011) 2.42
Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels. FASEB J (2013) 2.16
Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation (2013) 2.10
Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1. Nat Med (2013) 1.98
Podocyte foot process effacement in postreperfusion allograft biopsies correlates with early recurrence of proteinuria in focal segmental glomerulosclerosis. Transplantation (2012) 1.89
The podocyte cytoskeleton--key to a functioning glomerulus in health and disease. Nat Rev Nephrol (2011) 1.86
Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol (2012) 1.83
CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance. Pediatr Nephrol (2013) 1.83
Recurrent focal segmental glomerulosclerosis after kidney transplantation. Pediatr Nephrol (2015) 1.73
TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation. Pediatr Nephrol (2012) 1.57
The epidemic of pediatric chronic kidney disease: the danger of skepticism. J Nephropathol (2012) 1.55
Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation. Transplantation (2015) 1.47
Clinical role of the renal transplant biopsy. Nat Rev Nephrol (2012) 1.46
APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. J Am Soc Nephrol (2011) 1.43
A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med (2014) 1.39
Decreased Expression of Connexin 43 Blunts the Progression of Experimental GN. J Am Soc Nephrol (2017) 1.38
Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci (2011) 1.37
A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney Int (2014) 1.33
The role of the podocyte in albumin filtration. Nat Rev Nephrol (2013) 1.26
Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol (2013) 1.20
Rituximab therapy in nephrotic syndrome: implications for patients' management. Nat Rev Nephrol (2013) 1.18
New developments in steroid-resistant nephrotic syndrome. Pediatr Nephrol (2012) 1.18
Recent progress in the pathophysiology and treatment of FSGS recurrence. Am J Transplant (2013) 1.13
Serum suPAR in patients with FSGS: trash or treasure? Pediatr Nephrol (2013) 1.13
Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial. J Am Soc Nephrol (2015) 1.12
Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study. Crit Care (2012) 1.05
Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphaVbeta3 integrin signaling in the glomerulus. PLoS One (2012) 1.05
A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR). J Biol Chem (2012) 1.03
Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatr Nephrol (2014) 1.02
Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. Nat Med (2016) 1.02
The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury. J Mol Med (Berl) (2012) 1.02
Cell-matrix adhesion of podocytes in physiology and disease. Nat Rev Nephrol (2013) 1.02
Childhood nephrotic syndrome--current and future therapies. Nat Rev Nephrol (2012) 1.02
ARHGDIA: a novel gene implicated in nephrotic syndrome. J Med Genet (2013) 1.01
Lipid biology of the podocyte--new perspectives offer new opportunities. Nat Rev Nephrol (2014) 0.99
Physical activity - an important preanalytical variable. Biochem Med (Zagreb) (2014) 0.99
Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis. BMC Med (2014) 0.98
The role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimental studies. Inflamm Res (2014) 0.98
The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review. J Transplant (2011) 0.97
Urokinase-type plasminogen activator receptor (uPAR) ligation induces a raft-localized integrin signaling switch that mediates the hypermotile phenotype of fibrotic fibroblasts. J Biol Chem (2014) 0.97
Nephrotic syndrome: components, connections, and angiopoietin-like 4-related therapeutics. J Am Soc Nephrol (2014) 0.96
Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS. Clin J Am Soc Nephrol (2014) 0.96
Podocyte GTPases regulate kidney filter dynamics. Kidney Int (2012) 0.96
Integrins in kidney disease. J Am Soc Nephrol (2013) 0.95
Podocyte-associated talin1 is critical for glomerular filtration barrier maintenance. J Clin Invest (2014) 0.94
Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor. J Biol Chem (2011) 0.94
Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol (2014) 0.94
Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes. Sci Rep (2015) 0.93
Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation (2013) 0.92
Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated β1-integrin endocytosis. Am J Physiol Renal Physiol (2015) 0.92
Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor. World J Nephrol (2013) 0.92
The pathogenesis of focal segmental glomerulosclerosis. Adv Chronic Kidney Dis (2014) 0.92
Biomarkers in nephrology: Core Curriculum 2013. Am J Kidney Dis (2013) 0.91
Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR. Case Rep Nephrol (2014) 0.91
Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis. Pediatr Nephrol (2014) 0.91
Rituximab treatment prevents the early development of proteinuria following pig-to-baboon xeno-kidney transplantation. J Am Soc Nephrol (2014) 0.90
The importance of podocyte adhesion for a healthy glomerulus. Front Endocrinol (Lausanne) (2014) 0.89
Experimental concerns regarding suPAR-related proteinuria. Nat Rev Nephrol (2017) 0.89
HIV-1 infected lymphoid organs upregulate expression and release of the cleaved form of uPAR that modulates chemotaxis and virus expression. PLoS One (2013) 0.89
Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence. J Am Soc Nephrol (2014) 0.89
Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease. Clin J Am Soc Nephrol (2014) 0.87
The glomerular filtration barrier: components and crosstalk. Int J Nephrol (2012) 0.87
Is there clinical value in measuring suPAR levels in FSGS? Clin J Am Soc Nephrol (2013) 0.87
Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View. J Immunol Res (2016) 0.87
Glomerular diseases: FSGS. Clin J Am Soc Nephrol (2013) 0.86
Urokinase receptor orchestrates the plasminogen system in airway epithelial cell function. Lung (2013) 0.86
The glomerular permeability factors in idiopathic nephrotic syndrome. Pediatr Nephrol (2015) 0.86
Pathophysiology and treatment of focal segmental glomerulosclerosis: the role of animal models. BMC Nephrol (2013) 0.85
LPS nephropathy in mice is ameliorated by IL-2 independently of regulatory T cells activity. PLoS One (2014) 0.85
Complement Activation in Patients with Focal Segmental Glomerulosclerosis. PLoS One (2015) 0.85
Podocyte-actin dynamics in health and disease. Nat Rev Nephrol (2016) 0.85
De novo glomerular diseases after renal transplantation. Clin J Am Soc Nephrol (2014) 0.84
Angiopoietin-like 3 induces podocyte F-actin rearrangement through integrin α(V)β₃/FAK/PI3K pathway-mediated Rac1 activation. Biomed Res Int (2013) 0.84
Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group. BMC Nephrol (2015) 0.84
Membrane trafficking in podocyte health and disease. Pediatr Nephrol (2012) 0.84
Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus. Sci Rep (2017) 0.84
Glycogen synthase kinase 3β dictates podocyte motility and focal adhesion turnover by modulating paxillin activity: implications for the protective effect of low-dose lithium in podocytopathy. Am J Pathol (2014) 0.83
Progress in pathogenesis of proteinuria. Int J Nephrol (2012) 0.83
Inflammation in HIV-infected patients: impact of HIV, lifestyle, body composition, and demography - a cross sectional cohort study. PLoS One (2012) 0.83
Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis. Pediatr Nephrol (2012) 0.82
Renal and Hematological Effects of CLCF-1, a B-Cell-Stimulating Cytokine of the IL-6 Family. J Immunol Res (2015) 0.82
Podocyte endocytosis in the regulation of the glomerular filtration barrier. Am J Physiol Renal Physiol (2015) 0.82
Successful Treatment of Focal Segmental Glomerulosclerosis after Kidney Transplantation with Plasma Exchange and Abatacept in a Patient with Juvenile Rheumatoid Arthritis. Case Rep Transplant (2016) 0.82
Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates. Biomed Res Int (2016) 0.82
A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues. Clin Kidney J (2015) 0.81
Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease. Case Rep Nephrol (2016) 0.81
suPAR and Team Nephrology. BMC Med (2014) 0.81
Permeability factors in focal and segmental glomerulosclerosis. Adv Chronic Kidney Dis (2014) 0.81
Vitronectin inhibits efferocytosis through interactions with apoptotic cells as well as with macrophages. J Immunol (2013) 0.81
An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases. Front Pediatr (2014) 0.81
Issues in solid-organ transplantation in children: translational research from bench to bedside. Clinics (Sao Paulo) (2014) 0.81
Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis. Korean J Intern Med (2014) 0.81
Pathogenesis of Focal Segmental Glomerulosclerosis. J Pathol Transl Med (2016) 0.81
Podocytes. F1000Res (2016) 0.81
Heat shock proteins HSP70 and MRJ cooperatively regulate cell adhesion and migration through urokinase receptor. BMC Cancer (2014) 0.80
Cyclic nucleotide signalling in kidney fibrosis. Int J Mol Sci (2015) 0.80
M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med (2009) 11.81
A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol (2002) 6.48
uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol (2002) 6.24
Early molecular events in the assembly of matrix adhesions at the leading edge of migrating cells. J Cell Sci (2003) 4.85
Synaptopodin: an actin-associated protein in telencephalic dendrites and renal podocytes. J Cell Biol (1997) 4.43
Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med (1996) 4.41
Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med (2006) 4.26
Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01
Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol (2010) 3.77
Pathogenesis of preeclampsia. Annu Rev Pathol (2010) 2.66
Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis (2004) 2.51
Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med (2010) 2.32
Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol (2010) 2.24
Mechanisms and consequences of affinity modulation of integrin alpha(V)beta(3) detected with a novel patch-engineered monovalent ligand. J Biol Chem (1999) 2.04
Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett (1994) 1.88
Potential role of soluble ST2 protein in idiopathic nephrotic syndrome recurrence following kidney transplantation. Am J Kidney Dis (2009) 1.77
Recurrence of idiopathic nephrotic syndrome after renal transplantation. Lancet (1972) 1.71
Topography of ligand-induced binding sites, including a novel cation-sensitive epitope (AP5) at the amino terminus, of the human integrin beta 3 subunit. J Biol Chem (1995) 1.70
Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood (2000) 1.69
Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol (2010) 1.61
A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J Clin Invest (2010) 1.61
"The FSGS factor:" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol (1999) 1.47
Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation (2009) 1.47
Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts. Pediatr Nephrol (1990) 1.44
Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest (2009) 1.41
Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant (2005) 1.38
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res (1998) 1.38
Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res (2008) 1.36
The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions. J Clin Invest (2000) 1.25
Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol (1991) 1.23
The urokinase receptor as an entertainer of signal transduction. Front Biosci (Landmark Ed) (2009) 1.21
Membrane-anchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/progenitor cells. J Clin Invest (2009) 1.19
Selective purification and characterization of adiponectin multimer species from human plasma. Biochem Biophys Res Commun (2007) 1.19
Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis (1994) 1.18
Proteinuria and immunity--an overstated relationship? N Engl J Med (2008) 1.14
c-mip impairs podocyte proximal signaling and induces heavy proteinuria. Sci Signal (2010) 1.12
Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia. Infect Immun (2000) 1.08
Outcomes after renal transplantation for FSGS in children. Pediatr Transplant (2004) 1.07
In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer. Cancer Res (2006) 1.04
Transmission of glomerular permeability factor from a mother to her child. N Engl J Med (2001) 0.96
Circulating permeability factors in the nephrotic syndrome: a fresh look at an old problem. J Am Soc Nephrol (2003) 0.96
Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy. Nephrol Dial Transplant (2004) 0.96
The bioactivity of plasma factors in focal segmental glomerulosclerosis. Nephron Exp Nephrol (2006) 0.96
Plasma immunadsorption treatment in patients with primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant (1998) 0.95
The PlA2 polymorphism of the platelet glycoprotein IIIA gene as a risk factor for acute renal allograft rejection. J Am Soc Nephrol (1999) 0.91
Recurrence of idiopathic nephrotic syndrome after renal transplantation. 1972. J Am Soc Nephrol (2001) 0.90
Platelet GP IIIA polymorphism HPA-1 (PLA1/2) is associated with hypertension as the primary cause for end-stage renal disease in hemodialysis patients from Greece. In Vivo (2009) 0.86
Genome sequencing in microfabricated high-density picolitre reactors. Nature (2005) 150.21
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int (2010) 12.06
Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med (2013) 9.87
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell (2011) 7.30
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol (2002) 6.48
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
Sequential therapies for proliferative lupus nephritis. N Engl J Med (2004) 5.96
Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell (2010) 5.77
Strict blood-pressure control and progression of renal failure in children. N Engl J Med (2009) 5.71
Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med (2013) 5.62
Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int (2005) 5.49
Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med (2011) 5.30
Global diversity in the human salivary microbiome. Genome Res (2009) 5.16
Metabolite identification via the Madison Metabolomics Consortium Database. Nat Biotechnol (2008) 5.12
The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med (2008) 5.01
Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med (2015) 4.85
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med (2015) 4.78
Cell type-specific gene expression differences in complex tissues. Nat Methods (2010) 4.75
Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest (2004) 4.65
Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA. Cell Res (2011) 4.55
IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest (2008) 4.12
Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A (2006) 4.10
Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol (2011) 4.09
Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01
Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA (2009) 3.83
Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med (2006) 3.72
Exchange-coupled nanocomposite magnets by nanoparticle self-assembly. Nature (2002) 3.71
The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation. Nature (2007) 3.55
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med (2007) 3.35
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation (2011) 3.33
Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med (2011) 3.28
Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens (2002) 3.21
The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat Med (2011) 3.20
Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med (2011) 3.19
Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science (2013) 3.17
Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet (2010) 3.15
Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens (2009) 3.13
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet (2013) 2.91
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest (2011) 2.90
Prevalence of mutations in renal developmental genes in children with renal hypodysplasia: results of the ESCAPE study. J Am Soc Nephrol (2006) 2.89
Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol (2012) 2.83
Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension (2007) 2.77
Urinary placental growth factor and risk of preeclampsia. JAMA (2005) 2.76
Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol (2006) 2.76
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int (2012) 2.74
Vascular endothelial growth factor-A and aldosterone: relevance to normal pregnancy and preeclampsia. Hypertension (2013) 2.70
Pathogenesis of preeclampsia. Annu Rev Pathol (2010) 2.66
Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med (2006) 2.65
MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med (2011) 2.65
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension (2007) 2.62
Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant (2004) 2.55
Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res (2011) 2.55
Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 2.55
Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J Infect Dis (2012) 2.53
Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci U S A (2003) 2.50
Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes. Kidney Int (2011) 2.50
Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation (2002) 2.47
The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility. J Immunol (2011) 2.44
Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner. J Clin Invest (2005) 2.39
Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. Am J Hum Genet (2011) 2.38
N-Benzyl-2-(2,6-dichloro-phen-oxy)-acetamide. Acta Crystallogr Sect E Struct Rep Online (2008) 2.36
Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes (2010) 2.36
Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*. Crit Care Med (2012) 2.32
Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol (2006) 2.32
Carotid artery intima-media thickness and distensibility in children and adolescents: reference values and role of body dimensions. Hypertension (2013) 2.31
SIX2 and BMP4 mutations associate with anomalous kidney development. J Am Soc Nephrol (2008) 2.30
Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. Am J Epidemiol (2014) 2.30
Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2011) 2.28
Control of the pattern-recognition receptor EFR by an ER protein complex in plant immunity. EMBO J (2009) 2.28
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A (2007) 2.25
When and why portal vein thrombosis matters in liver transplantation: a critical audit of 174 cases. Ann Surg (2014) 2.23
Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy (2013) 2.22
Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension (2005) 2.22
Histone demethylase UTX-1 regulates C. elegans life span by targeting the insulin/IGF-1 signaling pathway. Cell Metab (2011) 2.22
COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J Clin Invest (2011) 2.21
Chronic stimulation of Nod2 mediates tolerance to bacterial products. Proc Natl Acad Sci U S A (2007) 2.20
Project management system for structural and functional proteomics: Sesame. J Struct Funct Genomics (2003) 2.19
New bioinformatics resources for metabolomics. Pac Symp Biocomput (2007) 2.19
Regulation of human airway epithelial cell IL-8 expression by MAP kinases. Am J Physiol Lung Cell Mol Physiol (2002) 2.19